Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

Jennifer CarrollJ

Jennifer Carroll

@Jennifer Carroll
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
About
Posts
1.4k
Topics
787
Shares
0
Groups
12
Followers
6
Following
0

Posts

Recent Best Controversial

  • Guideline terminology: Canadian, US/North American, International
    Jennifer CarrollJ Jennifer Carroll

    Hey @HollyMed

    Yes, per the copy "In the scenario described above where guidelines lower in the aforementioned hierarchy are being used over the available US guidelines, evidence must be provided to support that these guidelines are a true reflection of Canadian practice". Note that there may be instances where we ask for more information about US guidelines. This is extremely rare and the rationale is disclosed during the review process. If you find yourself in this rare instance, please reach out to the reviewer for clarification.

    Claims & Support/References for Claims

  • Guideline terminology: Canadian, US/North American, International
    Jennifer CarrollJ Jennifer Carroll

    Hey @HollyMed

    Please see Q&A 593.

    Claims & Support/References for Claims

  • Middle level fair balance linking to high-level fair balance
    Jennifer CarrollJ Jennifer Carroll

    @Jennifer_CM
    Example 3 appears to be about the product monograph web link destination. The original question above is about linking middle level fair balance to highest level fair balance. Linking middle level fair balance to highest requires that it’s within the same tool or directly attached. A print journal ad is not the same medium as a URL link (web based) and therefore would not be acceptable.

    Claims & Support/References for Claims

  • 577 - Hi - I understand that as per Section 6.6iv, an email informing HCPs about 'updated provincial formulary criteria for Drug X' would be considered PAAB exempt (if there were no linkage to therapeutic or promotional claims). Could you provide clarification on whether including a website link to the full formulary list of a province would still be considered exempt? Note that this formulary list contains criteria specific to Drug X.
    Jennifer CarrollJ Jennifer Carroll

    Hey @ALee
    “Indirect link to a general formulary/Provincial homepage” is the same as “full formulary list of a province”. As per the response above, this would not be considered exempt.

    Linkage Issues

  • Guidance on Patient Reported Outcomes
    Jennifer CarrollJ Jennifer Carroll

    Hi tk2022

    Please see our more recent “Guidance on Real World Evidence/Data” for criteria and direction on the presentation of RWE in advertising to health care professionals. Please also see our "Guidance on the use of the Attention Icon" regarding unblinded data.

    Guidance on Code Application

  • Consensus Guidelines
    Jennifer CarrollJ Jennifer Carroll

    Hi @megancouture

    Claims based on acceptable, authoritative consensus guidelines do not need to be verbatim from the reference. However, it must capture the recommendation accurately and within context. It must not impart a new or different meaning than the guidelines.

    PAAB Code

  • Clinical Guidelines
    Jennifer CarrollJ Jennifer Carroll

    A sale representative may leave a physician a full, unedited copy of a published, authoritative consensus guideline for a given condition. Please see the linked document on “What constitutes current medical opinion and practice?”. Depending on the nature of the visit, please also be reminded that distribution of material by a sales representative may constitute an act of advertising and should adhere to the advertising regulations, e.g. product specific guidelines on off label use would be a violation of the regulations.

    PAAB Code

  • Presenting AE rates using a higher incidence threshold than what is used in the PM
    Jennifer CarrollJ Jennifer Carroll

    Hello @dmauri

    PAAB will generally consider alternate cut offs from the TMA if it does not appear to be minimizing the risks of the product. The alternate cut-offs should not remove pertinent ADRs/safety information that would otherwise be important to the product and within the therapeutic landscape. The TMA should also not have other safety considerations that would preclude the higher percentage cutoff.

    Claims & Support/References for Claims

  • Fair Balance required for email linking to clincial paper
    Jennifer CarrollJ Jennifer Carroll

    Good Morning @Jennifer_CM

    Linking out to an unedited acceptable reprint would not render the email subject to highest level fair balance. The level of fair balance would be assessed based on the content of the email body in combination with the linked content. Therefore, it’s likely that the level of fair balance could be lowest level if the body copy does not prompt middle or highest itself as per the PAAB Guidance on Base Fair Balance Level Selection and Placement (HCP Advertising).

    PAAB Code

  • Clarification on Product Available now! message in the APS
    Jennifer CarrollJ Jennifer Carroll

    Hey @Supriya

    This appears to be a specific question about a specific piece. Copy around “new product availability” is broadly open to interpretation. PAAB would also need to see the third-party program site to assess the combination of all messaging within the piece and the linked content. We suggest submitting for an opinion.

    General Discussion

  • Promotional activities on-line
    Jennifer CarrollJ Jennifer Carroll

    Hey @Pauvian

    Advertising in a consumer space must meet the consumer regulations (i.e. does not exceed name, price, quantity for prescription (Rx) products or treatments for schedule A diseases). We would advise against including the DIN as this is a standard mechanism for gating patient information. Including the DIN would require assessment of all patient sites for the product to ensure this list is not promoting the password to the general public.

    Note that the question is in response to a “list”. The website appears to contain additional elements (such as pictures) which may render the site in non-compliance. We’d recommend submitting for an opinion in order to fully assess the complexities of the proposed activity.

    PAAB Code

  • Clarification on indication inclusion in multi-Product APS
    Jennifer CarrollJ Jennifer Carroll

    Hey @Supriya

    This appears to be a specific question about a specific piece. The piece should be submitted for assessment. The forum is for general questions. As an example, a general question here might be “Is the inclusion of an indication statement required in materials directed exclusively to healthcare professionals, where no therapeutic or pharmacologic claims are presented”. The answer to this question would be, that the indication is not required when there are no marketing benefit or therapeutic claims (see Marketing benefit claims: What are they and what level of support do they require?).

    General Discussion

  • Price Comparisons
    Jennifer CarrollJ Jennifer Carroll

    Good Morning @Constance
    PAAB would need additional information to make the assessment of the claim proposed above. There are many considerations outside of just the source such as, does it suggest equivalence between products on a per unit basis and what is the intent of the per unit comparison. Given these unknowns, it is difficult to provide a definitive answer in a general space. We suggest submitting the copy for review.

    Claims & Support/References for Claims

  • Prescription Pads/Tools
    Jennifer CarrollJ Jennifer Carroll

    Hey @GMC
    This copy would be reviewed in the context of the entirety of the piece. The context of the message “dispensed as written” will matter. See also the PAAB advisory on Advertising messages referring to "no sub".

    PAAB Code

  • Assessment of Risk Management Tools (HCP/Patient)
    Jennifer CarrollJ Jennifer Carroll

    Hey @mhouzer

    The difference between the Standard 4-day initial review of RMTs and submitting as an ARO-4 is that the subsequent revision turnaround time will be an expedited 2-days rather than the standard 3-days. If you anticipate needing a few rounds of back and forth, this can be a good option to get to your final letter more quickly.

    Comments & Feedback

  • PAAB AI Regulatory Model - Opt-in deadline - Thursday
    Jennifer CarrollJ Jennifer Carroll

    📆AI MODEL - Phase I Testing Opt-In Deadline!

    @Manufacturer the Pharmaceutical Advertising Advisory Board (PAAB) is taking a significant step forward in innovation by launching the first phase of testing of our ground-breaking AI model on live files starting May 1st.

    On April 1st, in preparation for launch, we sent an eblast to industry announcing the deadline for full opt-in was now set for May 1st. Manufacturers who opt-in after the May 1st deadline will likely need to wait until a sufficient number of additional opt-ins are accumulated. This grouping of late opt-ins is intended to support cost-effectiveness.

    This initiative marks a major milestone in enhancing the efficiency, consistency, and effectiveness of advertising review processes for our industry. Ensuring that preclearance keeps pace with the speed and quantity of specialization afforded through AI adoption across the industry.

    If you have not yet reached out to PAAB and want to be among the first to experience the benefits of this exciting new project, please contact info@paab.ca today.

    @Agency we'll be reaching out shortly for your collaboration on the AI driven augmentation of the submission process.

    Cheers
    PAAAB

    Announcements

  • Pooled long-term extension data
    Jennifer CarrollJ Jennifer Carroll

    Good Morning @HollyMed

    Pooled data is not acceptable even if part of a pre-planned long-term extension study.

    Miscellaneous

  • Clarification on indication inclusion in multi-Product APS
    Jennifer CarrollJ Jennifer Carroll

    Good Morning @Supriya

    We assume that you are referring to a patient targeted APS. As a patient would not have a prescription for all the products, this would contravene the direct-to-consumer advertising (DTCA) regulations (Section C.01.044 of the Food and Drugs Act Regulations) to create a link to the therapeutic use (i.e. indication could not be included) for products they are not prescribed. While the three base levels of fair balance apply only to HCP-targeted APS, a weblink to the Terms of Market Authorization (TMA) links the therapeutic use, a violation of the DTCA regulations.

    General Discussion

  • Client Survey Report - 2024
    Jennifer CarrollJ Jennifer Carroll

    🔍 What did we learn from you in 2024?

    In October, PAAB sent out our Client Survey to better understand your experience with us — what’s working, what’s not, and where we can grow together.

    This year’s survey offered deeper insights into awareness of recent Code and guidance updates, and helped us identify how we can better support your PAAB experience moving forward.

    🙌 Thank you to everyone who participated. Your feedback is already driving improvements across training, review practices, and communication.

    📄 Check out the full Customer Insights Report

    Announcements

  • Adverse events rates that are not included in the PM
    Jennifer CarrollJ Jennifer Carroll

    Hi @dmauri

    This would not apply to comparative data. As per the first sentence “statistical analysis to support inclusion of comparative therapeutic data” is required. The comment also states that the AEs have to be aligned. Your original question appears to suggest that you are looking to speak to AEs which are not presented in the TMA and therefore would be difficult to demonstrate alignment.

    Claims & Support/References for Claims
  • Login

  • Don't have an account? Register

  • Login or register to search.
  • First post
    Last post
0
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups